key: cord-0015288-6gwvfh7v
authors: Güner, Ahmet; Kalçık, Macit; Kalkan, Semih; Özkan, Mehmet
title: Management of obstructive prosthetic heart valve thrombosis: thrombolytic therapy or anticoagulation?
date: 2021-02-10
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2021.01.026
sha: 3d5847f62e2b23d9eb49160edb531bb5320fa2a1
doc_id: 15288
cord_uid: 6gwvfh7v

nan

We have recently read with great interest the article by Gisbert et al entitled ''Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19'' [1] . We appreciate the authors for their case reports describing the successful management of prosthetic valve thrombosis (PVT) secondary to COVID-19. On the other hand, we believe that there are several major drawbacks that need to be addressed.

First of all, during the past two decades, thrombolytic therapy (TT) has increasingly become an alternative to surgery as a first-line therapy in patients with obstructive PVT [2] . Previously, Ozkan et al reported regarding the safety and efficacy of TT regimens with low-dose and slow infusion tissue plasminogen activator [2] . The 2020 ACC/AHA guideline for the management of patients with valvular heart disease now recommends urgent initial treatment with either slow-infusion low-dose TT or emergency surgery for obstructive PVT as first-line treatment strategies with class I-B indications [3] . The most obvious problem with this case report is already evident in the abstract is that anticoagulation is preferred, although the recommendations for major cardiovascular guidelines thrombolytic therapy are clear. Perhaps the authors can explain the reasons for not applying TT or surgical therapy.

Second, one of the treatment options for PVT is intensive anticoagulation. The effectiveness of anticoagulation in the treatment of PVT was based on data from a limited number of publications. It has been reported that the prognosis for a small asymptomatic thrombus (length <10 mm) is favorable with optimization of anticoagulant therapy [2, 3] . Recently, we reported that the success rate of anticoagulation therapy containing heparin in patients with PVT was 46.8% [4] . The readers may wonder why anticoagulation with the low success rate was preferred to the treatment of PVT over TT, whose effectiveness and safety has been proven by numerous studies.

Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19

Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of

Online ahead of print

The relationship between heparanase levels, thrombus burden and thromboembolism in patients receiving unfractionated heparin treatment for prosthetic valve thrombosis